Verastem (VSTM) Reports Q1 Loss of $0.46/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Verastem to Present at 2015 UBS Global Health Care Conference
May 12, 2015 7:00 AM EDTBOSTON--(BUSINESS WIRE)-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will present at the 2015 UBS Global Healthcare Conference on Tuesday, May 19 at... More
Verastem Reports First Quarter 2015 Financial and Corporate Results
May 11, 2015 4:05 PM EDTCOMMAND Interim Analysis Anticipated in Third Quarter 2015
BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the first quarter ended March 31, 2015, and also provided an overview of certain corporate accomplishments and plans.
The team continues to efficiently execute on each of our ongoing programs targeting cancer stem cells, said Robert Forrester, President and Chief Executive Officer of Verastem. Accrual to the COMMAND study evaluating our cancer stem cell inhibitor, VS-6063, as a switch... More
